AMN / Hyderabad
Hyderabad-based Reddy’s Laboratories Ltd has announced that it has launched Sevelamer Carbonate Tablets, 800 mg,a therapeutic equivalent generic version of Renvela (sevelamer carbonate) Tablets, a trade mark of Genzyme Corporation, in the US Market
The drug was approved by the US Food and Drug Administration (USFDA), the pharmacutical company said in statement here on Friday.
“We are very pleased to bring Sevelamer Carbonate Tablets to market at this time,” says Alok Sonig, Executive Vice President and Head of the North America Generics business at Dr. Reddy’s.
“This launch represents Dr. Reddy’s expertise and commitment to provide affordable alternatives for complex, limited-competition products to market.” This is the Company’s eighth overall and fourth limited-competition launch this fiscal year.
The Renvela® brand and generic had U.S. sales of approximately $1.88 billion MAT for the most recent twelve months ending in July 2017 according to IMS Health*.
Dr. Reddy’s Sevelamer Carbonate Tablets, 800 mg are available in the bottle count size of 270 tablets.
Renvela® is a trademark of Genzyme Corporation
FOLLOW INDIAN AWAAZ ON TWITTER